Follow
Дніпровський державний медичний університет | Dnipro State Medical University | ДДМУ
Дніпровський державний медичний університет | Dnipro State Medical University | ДДМУ
Дніпровський державний медичний університет
Verified email at dma.dp.ua - Homepage
Title
Cited by
Cited by
Year
Edoxaban versus warfarin in patients with atrial fibrillation
RP Giugliano, CT Ruff, E Braunwald, SA Murphy, SD Wiviott, JL Halperin, ...
New England Journal of Medicine 369 (22), 2093-2104, 2013
58052013
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
C Robert, L Thomas, I Bondarenko, S O’Day, J Weber, C Garbe, ...
N Engl J Med, 2517-2526, 2011
54022011
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ...
The Lancet 393 (10183), 1819-1830, 2019
28472019
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ...
New England Journal of Medicine 380 (12), 1116-1127, 2019
28022019
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
C Bokemeyer, I Bondarenko, A Makhson, JT Hartmann, J Aparicio, ...
JOURNAL OF CLINICAL ONCOLOGY| 10th World Congress on Gastrointestinal …, 2009
21692009
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptorpositive, HER2-negative …
The lancet oncology 16 (1), 25-35, 2015
21022015
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ...
NEW ENGLAND JOURNAL OF MEDICINE 371 (20), 1877-1888, 2014
19722014
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous …
M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, ...
LANCET ONCOLOGY 17 (4), 425-439, 2016
17402016
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ...
LANCET 386 (9992), 444-451, 2015
15332015
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label …
L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet 394 (10212), 1929-1939, 2019
15252019
Comparison of fondaparinux and enoxaparin in acute coronary syndromes
Fifth Organization to Assess Strategies in Acute Ischemic Syndromes ...
New England Journal of Medicine 354 (14), 1464-1476, 2006
14712006
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ...
The Lancet 392 (10157), 1519-1529, 2018
13322018
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor …
NJ Robert, V Dieras, J Glaspy, AM Brufsky, I Bondarenko, ON Lipatov, ...
JOURNAL OF CLINICAL ONCOLOGY 29 (10), 1252-1260, 2011
12122011
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind …
TJ Lynch, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, ...
Journal of clinical oncology 30 (17), 2046-2054, 2012
11982012
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
C Robert, JJ Grob, D Stroyakovskiy, B Karaszewska, A Hauschild, ...
New England Journal of Medicine 381 (7), 626-636, 2019
11492019
Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial
SS Hassan, R Romero, D Vidyadhari, S Fusey, JK Baxter, M Khandelwal, ...
ULTRASOUND IN OBSTETRICS & GYNECOLOGY 38 (1), 18-31, 2011
11312011
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised …
M Reck, R Kaiser, A Mellemgaard, JY Douillard, S Orlov, M Krzakowski, ...
LANCET ONCOLOGY 15 (2), 143-155, 2014
10782014
Overall survival with palbociclib and fulvestrant in advanced breast cancer
NC Turner, DJ Slamon, J Ro, I Bondarenko, SA Im, N Masuda, M Colleoni, ...
New England journal of medicine 379 (20), 1926-1936, 2018
10342018
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
C Bokemeyer, I Bondarenko, JT Hartmann, F de Braud, G Schuch, ...
ANNALS OF ONCOLOGY 22 (7), 1535-1546, 2011
10032011
Компьютерная зависимость: формирование, диагностика, коррекция и профилактика
ЛН Юрьева, ТЮ Больбот
Днепропетровск: Пороги 196, 2006
9332006
The system can't perform the operation now. Try again later.
Articles 1–20